Securities code: 000513, 01513 securities abbreviation: Livzon Pharmaceutical Group Inc(000513) , Lizhu pharmaceutical Announcement No.: 2022-004 Livzon Pharmaceutical Group Inc(000513) progress announcement on repurchase of H shares
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Livzon Pharmaceutical Group Inc(000513) (hereinafter referred to as “the company”) convened the company’s 2020 annual general meeting of shareholders, the first A-share shareholders’ meeting in 2021 and the first H-share shareholders’ meeting in 2021 on May 20, 2021, and deliberated and adopted the general authorization on granting the board of directors to repurchase H shares of the company. For the implementation and progress of this round of repurchase of H shares, please refer to the H share announcements disclosed by the company on December 7, 2021, January 6, 2022 and daily synchronization. The progress of the company’s current round of repurchase of H shares is hereby announced as follows:
As of January 31, 2022, the company has repurchased 3404400 H shares of the company in this round, accounting for about 1.09% of the total issued H shares of the company and 0.36% of the total shares of the company. The highest repurchase price is HK $27.00/share and the lowest price is HK $24.70/share. The total amount of funds used is HK $87004410.00 (excluding transaction costs). The above repurchase is in line with the general authorization of the company’s H-share repurchase. The board of directors of the company will, in strict accordance with relevant regulations, implement H-share repurchase within the scope of general authorization of the general meeting of shareholders and timely perform the obligation of information disclosure. Please pay attention to investment risks.
It is hereby announced.
Livzon Pharmaceutical Group Inc(000513) board of directors February 9, 2022
